Mr. Joel Shacker reports

CORE ONE'S AKOME RECEIVES POSITIVE PRELIMINARY STAGE 1 ANIMAL MODEL STUDY RESULTS FOR BIO-COMPOUND TARGETING ALZHEIMER'S AND PARKINSON'S DISEASE

Core One Labs Inc. has released positive results from its first round of stage 1 animal model studies, conducted by its research partners at the Universitat de Barcelona, Barcelona, Spain, on behalf of the company's wholly owned subsidiary, Akome Biotechnologies Inc.

Akome's stage 1 animal model studies (in vivo, or within living organisms) use the nematode Caenorhabditis elegans animal model, and evaluate Akome's carefully selected and various biocompounds individually in their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer's disease, Parkinson's disease, Ischemic stroke and depression, (collectively the targeted diseases).

The first round of these stage 1 animal model studies focused on examining the pharmacological effects of just one of Akome's five selected plant bioactive compounds (biocompound A), after exposure to the central nervous system of the model. Investigators assessed the impact of biocompound A on the motility of a specific C. elegans strain (CL2006) -- a nematode strain containing a transgene responsible for progressive, adult-onset paralysis (which is widely used for Alzheimer's and Parkinson's drug discovery research) and are pleased to share the positive preliminary results.

The preliminary results from biocompound A stage 1 studies have shown favourable effects supporting Akome's hypothesis that biocompound A has the potential to significantly reduce motor dysfunction, a dysfunction associated with Parkinson's, and prevalent in late stages of Alzheimer's. This effect by biocompound A on the CL2006 C. elegans strain model is showing effects similar to those observed in the same model with drugs currently approved for the treatment of Parkinson's disease. The significance of biocompound A having similar results to that of currently approved Parkinson's drug treatments, is that biocompound A is a natural plant derivative.

These extremely promising and positive initial results from the stage 1 animal model study for biocompound A holds substantial significance for Akome's further progression toward advanced animal model studies. In the upcoming weeks, the company anticipates presenting results from additional stage 1 animal model studies for the remaining Akome biocompounds, and targeted diseases which are the subject of the company's patent-pending psychedelic drug formulations.

Following results from the remaining Akome biocompound stage 1 studies, investigators will proceed with stage 2 animal model studies, examining the synergistic effect of the biocompounds in combination with N, N-dimethyltryptamine (DMT) and other psychedelic compounds.

"Successful results from Akome's completed animal model studies could pave the way for transformative advancements in the company's development of psychedelic drug formulations that target Parkinson's and Alzheimer's, stroke, and depression more effectively, and at this point we seem to be heading in the right direction. Akome's biocompounds have the potential to positively affect the lives of millions of individuals afflicted with debilitating mental health afflictions and life-threatening neurological diseases," stated Joel Shacker, Core One's chief executive officer.

About Core One Labs Inc.

Core One is a life science biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the integration of novel delivery systems technology.

The company has a multifaceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelic market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100-per-cent-owned subsidiary Akome Biotech Ltd., and three provisional patents under its other 100-per-cent-owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics, the company intends to integrate a rollout of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

We seek Safe Harbor.